60 Degrees Pharmaceuticals (SXTP) Change in Cash (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Change in Cash of $1.8 million for Q1 2026, up 1.98% year-over-year from $1.8 million in Q1 2025, and up 170.14% quarter-over-quarter from -$2.6 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Change in Cash (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Change in Cash for 5 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 1.98% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at -$113740.0 (down 120.43% YoY), while the FY2025 annual figure was -$149288.0, up 69.1% from the prior year.
- Change in Cash improved to $1.8 million in Q1 2026 per SXTP's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Change in Cash topped out at $2.2 million in Q3 2023 and bottomed at -$2.6 million in Q4 2025.
- Historically, Change in Cash has averaged $172420.7 across 5 years, with a median of -$76055.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Cash jumped 804.83% — and 2024, when it tumbled 11967.18%.
- 60 Degrees Pharmaceuticals' Change in Cash stood at -$174528.0 in 2022, then soared by 56.42% to -$76055.0 in 2023, then tumbled by 2058.09% to -$1.6 million in 2024, then slumped by 58.76% to -$2.6 million in 2025, then soared by 170.14% to $1.8 million in 2026.
- Business Quant data shows SXTP's Change in Cash at $1.8 million in Q1 2026, -$2.6 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | -2.61 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | -1.32 Mn |
| Mar 31, 2024 | 752,215.00 |
| Dec 31, 2023 | -76,055.00 |
| Sep 30, 2023 | 2.20 Mn |
| Jun 30, 2023 | -10,923.00 |
| Mar 31, 2023 | -234,872.00 |
| Dec 31, 2022 | -174,528.00 |
| Sep 30, 2022 | -312,057.00 |